列表页top

您现在的位置:新闻首页>综合资讯

New Analysis Supports LongTerm

2020-11-06 21:40第三视角网编辑:admin人气:


New Analysis Supports Long-Term Treatment with nintedanib in SSc-ILD Patients1

Interim analysis demonstrated long-term safety and suggested a sustained effect of nintedanib on slowing lung function decline in patients with SSc-ILD1
Safety and efficacy profile of nintedanib was consistent with the Phase III SENSCIS® trial, according to this analysis1

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced results from an interim analysis of the SENSCIS®-ON trial evaluating nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD). The new analysis was published online as part of ACR Convergence 2020.

SENSCIS-ON is an open-label extension trial to assess the long-term safety of nintedanib in patients with SSc-ILD who completed the Phase III SENSCIS® trial. The study is evaluating the absolute and relative change from baseline in the forced vital capacity (FVC) as a measure of lung function over 52 weeks.1,2

The interim analysis showed that the safety profile of nintedanib in SENSCIS-ON was consistent with that reported over 52 weeks in the SENSCIS trial with diarrhea being the most frequently reported adverse event.1 The analysis showed that 347 patients in the extension study who received nintedanib demonstrated a decrease in FVC over 52 weeks as did patients in the SENSCIS study.1 The average change in FVC from baseline to week 52 of SENSCIS-ON was −51.3 mL in all patients treated in SENSCIS-ON, while the change from baseline to week 52 in the SENSCIS trial was −42.7 mL.1

“Boehringer Ingelheim is continuously committed to providing scientific data, offering clinicians more confidence in treating patients with SSc-ILD,” commented Dr. Susanne Stowasser, Associate Medical Head Pulmonology at Boehringer Ingelheim. “We are thrilled to share the new data demonstrating a similar consistent safety profile of nintedanib in people living with SSc-ILD and suggesting a sustained effect in slowing lung function decline.”

~Ends~



(来源:国际文传电讯社)

已推荐
0
  • 凡本网注明"来源:第三视角网的所有作品,版权均属于中第三视角网,转载请必须注明中第三视角网,http://www.dsshijiao.com。违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。





图说新闻

更多>>
月底通车!台辉高速豫鲁界至台前互通段顺利完成交工验收检测

月底通车!台辉高速豫鲁界至台前互通段顺利完成